Quick Answer
Lexeo Therapeutics, Inc. reported Diluted EPS of $1.86 per share (loss) for fiscal year 2025.
Lexeo Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.86 | +39.8% |
| 2024 | -$3.09 | +75.1% |
| 2023 | -$12.40 | +65.9% |
| 2022 | -$36.36 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.33 | +62.9% | +45.0% |
| June 30, 2025 | -$0.60 | +6.3% | +39.4% |
| March 31, 2025 | -$0.99 | -28.6% | -11.2% |
| September 30, 2024 | -$0.89 | +92.8% | -39.1% |
| June 30, 2024 | -$0.64 | +92.3% | +16.9% |
| March 31, 2024 | -$0.77 | +93.4% | +93.8% |
| September 30, 2023 | -$12.36 | -19.1% | -48.9% |
| June 30, 2023 | -$8.30 | — | +28.3% |
- Lexeo Therapeutics, Inc. showed an increase of +39.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Lexeo Therapeutics, Inc.’s diluted eps has grown by 94.9% (from $36.36 per share (loss) to $1.86 per share (loss)).
- The most recent figure is from Lexeo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: